ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give ICU Medical an average recommendation of "Moderate Buy" based on five firms (1 sell, 1 hold, 2 buy, 1 strong buy) with an average 12‑month price target of $179.33.
• Most recent quarter: EPS of $1.91 beat the $1.68 estimate while revenue of $535.9M missed the $541.2M estimate and was down 14.1% year‑over‑year; the company issued FY2026 guidance of 7.75–8.45 EPS.
• Institutional investors own 96.10% of the stock, with several funds recently increasing stakes (e.g., UBS +32.4%, Intech +38.6%); the shares opened at $124.19, down 2.7%, with a market cap around $3.10 billion.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $179.3333.

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Sunday, February 15th. Weiss Ratings restated a "sell (d-)" rating on shares of ICU Medical in a research report on Thursday, January 22nd. KeyCorp upped their target price on ICU Medical from $175.00 to $180.00 and gave the stock an "overweight" rating in a research note on Friday, February 20th. Finally, Piper Sandler increased their target price on ICU Medical from $172.00 to $178.00 and gave the company an "overweight" rating in a research report on Friday, February 20th.

Hedge Funds Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICUI. AQR Capital Management LLC increased its stake in shares of ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock worth $1,297,000 after purchasing an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier's stock valued at $1,772,000 after buying an additional 560 shares in the last quarter. United Services Automobile Association acquired a new stake in ICU Medical in the 1st quarter worth about $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier's stock worth $9,472,000 after buying an additional 16,680 shares during the last quarter. Finally, Intech Investment Management LLC increased its stake in ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier's stock worth $1,658,000 after buying an additional 3,326 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Down 2.7%

ICUI opened at $124.19 on Friday. The company has a fifty day moving average of $143.34 and a two-hundred day moving average of $138.02. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 6,212.61, a PEG ratio of 1.84 and a beta of 0.79. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.15 and a current ratio of 2.39.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The business had revenue of $535.94 million for the quarter, compared to analyst estimates of $541.20 million. During the same period in the prior year, the company posted $2.11 EPS. The company's revenue for the quarter was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, research analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.